StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
INMBVery BearishIndustry Newsnews
High materiality10/10

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Jul 4, 2025, 9:41 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Shkreli's claims and historical trends suggest significant downward pressure. Similar biotech stocks have reacted similarly to critical announcements.

AI summary

What happened, with direct paths to the underlying reporting

Martin Shkreli predicts a 90% drop for INMB shares. Shkreli cites weak Phase 1 trial data as a major concern. Recent enthusiasm followed INMB's 44% surge relating to XPro1595. BMF Reports supports Shkreli's critique of INMB's scientific integrity. INMB shares fell by 15% on Friday ahead of Shkreli's post.

  • Martin Shkreli predicts a 90% drop for INMB shares.
  • Shkreli cites weak Phase 1 trial data as a major concern.
  • Recent enthusiasm followed INMB's 44% surge relating to XPro1595.
  • BMF Reports supports Shkreli's critique of INMB's scientific integrity.
  • INMB shares fell by 15% on Friday ahead of Shkreli's post.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event